Prostate Cancer: Radiation therapy

[1]  Yoshiya Yamada,et al.  Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. , 2008, International journal of radiation oncology, biology, physics.

[2]  Y. Yamada,et al.  Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[3]  Charles R. Thomas,et al.  An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. , 2007, International journal of radiation oncology, biology, physics.

[4]  Ming-Hui Chen,et al.  Magnetic resonance image‐guided salvage brachytherapy after radiation in select men who initially presented with favorable‐risk prostate cancer , 2007, Cancer.

[5]  A. D'Amico,et al.  Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate‐specific antigen failure , 2007, Cancer.

[6]  F. Mottaghy,et al.  Evaluation of [11C]‐choline positron‐emission/computed tomography in patients with increasing prostate‐specific antigen levels after primary treatment for prostate cancer , 2007, BJU international.

[7]  H. Hricak,et al.  Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. , 2007, International journal of radiation oncology, biology, physics.

[8]  Christopher A Peters,et al.  A genetically determined dose-volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy. , 2007, International journal of radiation oncology, biology, physics.

[9]  Peter Bownes,et al.  High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  K. Wallner,et al.  Long‐term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high‐risk features , 2007, Cancer.

[11]  M. Kattan,et al.  Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer. , 2007, Urology.

[12]  G. Pond,et al.  The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry. , 2007, Brachytherapy.

[13]  A. Su,et al.  Chronic Genitourinary and Gastrointestinal Toxicity of Prostate Cancer Patients Undergoing Pelvic Radiotherapy With Intensity-Modulated Versus 4-Field Technique , 2007, American journal of clinical oncology.

[14]  M. Parmar,et al.  Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. , 2007, The Lancet. Oncology.

[15]  W. van Putten,et al.  Sexual function after three-dimensional conformal radiotherapy for prostate cancer: results from a dose-escalation trial. , 2007, International journal of radiation oncology, biology, physics.

[16]  H. Zaidi,et al.  18F‐choline and/or 11C‐acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate‐specific antigen values (<1 ng/mL) after radical prostatectomy , 2007, BJU international.

[17]  E. Messing,et al.  Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Shah,et al.  Percent positive biopsy cores as a prognostic factor for prostate cancer treated with external beam radiation. , 2007, Urology.

[19]  L. Kestin,et al.  Use of Individual Fraction Size Data from 3756 Patients to Directly Determine the α/β Ratio of Prostate Cancer , 2007 .

[20]  S. Tyldesley,et al.  Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy. , 2007, International journal of radiation oncology, biology, physics.

[21]  J. Pouliot,et al.  Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. , 2007, International journal of radiation oncology, biology, physics.

[22]  Louis Potters,et al.  Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. , 2007, International journal of radiation oncology, biology, physics.

[23]  R. Stock,et al.  Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. , 2007, Urology.

[24]  Moyed Miften,et al.  Patient dose and image quality from mega-voltage cone beam computed tomography imaging. , 2007, Medical physics.

[25]  D. Theodorescu,et al.  Case-matched comparison of contemporary radiation therapy to surgery in patients with locally advanced prostate cancer. , 2006, International journal of radiation oncology, biology, physics.

[26]  E. Messing,et al.  Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. , 2006, JAMA.

[27]  R. Holloway,et al.  Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. , 2006, International journal of radiation oncology, biology, physics.

[28]  Neal Goldstein,et al.  High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study. , 2006, International journal of radiation oncology, biology, physics.

[29]  Yoshiya Yamada,et al.  Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. , 2006, The Journal of urology.

[30]  J. Crook,et al.  Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Steve Webb,et al.  Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397). , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[32]  M. Heckman,et al.  Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. , 2006, The Journal of urology.

[33]  Michael W Kattan,et al.  Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Damber,et al.  Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone. , 2006, The Journal of urology.

[35]  Paul Schellhammer,et al.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.

[36]  Marco Zaider,et al.  Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer. , 2006, Brachytherapy.

[37]  M. Kattan,et al.  Nomograms for prostate cancer , 2006, BJU international.

[38]  Evis Sala,et al.  Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. , 2006, Radiology.

[39]  Joos V Lebesque,et al.  Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  T. Wilt,et al.  Neo‐adjuvant and adjuvant hormone therapy for localised prostate cancer , 2006 .

[41]  H. Hricak,et al.  Endorectal MR imaging in the evaluation of seminal vesicle invasion: diagnostic accuracy and multivariate feature analysis. , 2006, Radiology.

[42]  A. Renshaw,et al.  Adult urologyUrological survey: urological oncology: prostate cancerPretreatment PSA Velocity and Risk of Death From Prostate Cancer Following External Beam Radiation Therapy , 2006 .

[43]  Patrick A Kupelian,et al.  Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. , 2005, International journal of radiation oncology, biology, physics.

[44]  A. Pollack,et al.  Parameters for treatment decisions for salvage radiation therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  A. D'Amico,et al.  Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  C. D’Este,et al.  Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. , 2005, The Lancet. Oncology.

[47]  Barry S Rosenstein,et al.  Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. , 2005, International journal of radiation oncology, biology, physics.

[48]  R. Stock,et al.  Salvage Prostate Brachytherapy Following Radiotherapy Failure , 2005 .

[49]  Daniel W. Miller,et al.  Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. , 2005, JAMA.

[50]  J. Brooks,et al.  Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  M. Piérart,et al.  Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911) , 2005, The Lancet.

[52]  Patrick A Kupelian,et al.  Initial experience with megavoltage (MV) CT guidance for daily prostate alignments. , 2005, International journal of radiation oncology, biology, physics.

[53]  J. Mulhall,et al.  The efficacy of sildenafil citrate following radiation therapy for prostate cancer: temporal considerations. , 2005, The Journal of urology.

[54]  P. Scardino,et al.  Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. , 2005, International journal of radiation oncology, biology, physics.

[55]  Wayne M Butler,et al.  Erectile function after prostate brachytherapy. , 2005, International journal of radiation oncology, biology, physics.

[56]  Leen Paelinck,et al.  The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotherapy. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[57]  J. Fowler,et al.  The radiobiology of prostate cancer including new aspects of fractionated radiotherapy , 2005, Acta oncologica.

[58]  A. Hanlon,et al.  Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation. , 2005, International journal of radiation oncology, biology, physics.

[59]  D. Grignon,et al.  Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. , 2005, International journal of radiation oncology, biology, physics.

[60]  Caitlin Gillan,et al.  Posttreatment Complications of Early‐Stage Prostate Cancer Patients: Brachytherapy Versus Three‐Dimensional Conformal Radiation Therapy , 2005, Cancer journal.

[61]  R. Stock,et al.  Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy. , 2005, The Journal of urology.

[62]  M. Kattan,et al.  Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. , 2005, Radiology.

[63]  Qing Guo,et al.  Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  Ping Xia,et al.  Low-dose megavoltage cone-beam CT for radiation therapy. , 2005, International journal of radiation oncology, biology, physics.

[65]  F. Critz,et al.  10-year disease-free survival rates after simultaneous irradiation for prostate cancer with a focus on calculation methodology. , 2004, The Journal of urology.

[66]  E. B. Butler,et al.  Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. , 2004, JAMA.

[67]  J. Manola,et al.  6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. , 2004, JAMA.

[68]  R. Stock,et al.  Combined modality treatment in the management of high-risk prostate cancer. , 2004, International journal of radiation oncology, biology, physics.

[69]  Ming-Hui Chen,et al.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. , 2004, The New England journal of medicine.

[70]  M. Regan,et al.  Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen. , 2004, The Journal of urology.

[71]  D. Baltas,et al.  3-D Conformal HDR Brachytherapy as Monotherapy for Localized Prostate Cancer , 2004, Strahlentherapie und Onkologie.

[72]  T. Mate,et al.  Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. , 2004, International journal of radiation oncology, biology, physics.

[73]  G. Gustafson,et al.  High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. , 2004, The Journal of urology.

[74]  A. Fortin,et al.  The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. , 2004, The Journal of urology.

[75]  W. Cavanagh,et al.  125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial. , 2003, International journal of radiation oncology, biology, physics.

[76]  J. Blasko,et al.  Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. , 2003, International journal of radiation oncology, biology, physics.

[77]  R. Stock,et al.  Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality. , 2003, International journal of radiation oncology, biology, physics.

[78]  D. Grignon,et al.  Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  W. J. Morris,et al.  Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  M. Cooperberg,et al.  National practice patterns and time trends in androgen ablation for localized prostate cancer. , 2003, Journal of the National Cancer Institute.

[81]  V. Nitti,et al.  American Urological Association Symptom Index for lower urinary tract symptoms in women: correlation with degree of bother and impact on quality of life. , 2003, Urology.

[82]  F. Hamdy,et al.  Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study. , 2003, Controlled clinical trials.

[83]  R K Valicenti,et al.  Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  R. Galalae,et al.  Fractionated perineal high-dose-rate temporary brachytherapy combined with external beam radiation in the treatment of localized prostate cancer: is lymph node sampling necessary? , 2003, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[85]  Adam P Dicker,et al.  Probability of late rectal morbidity in 125I prostate brachytherapy. , 2003, International journal of radiation oncology, biology, physics.

[86]  Marco Zaider,et al.  Towards integrating functional imaging in the treatment of prostate cancer with radiation: the registration of the MR spectroscopy imaging to ultrasound/CT images and its implementation in treatment planning. , 2002, International journal of radiation oncology, biology, physics.

[87]  L. Potters,et al.  Clinical investigation: prostateRadical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer , 2004 .

[88]  C. Reddy,et al.  Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  J. Wong,et al.  Flat-panel cone-beam computed tomography for image-guided radiation therapy. , 2002, International journal of radiation oncology, biology, physics.

[90]  George Starkschall,et al.  Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. , 2002, International journal of radiation oncology, biology, physics.

[91]  Jacques Bernier,et al.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial , 2002, The Lancet.

[92]  A W Partin,et al.  Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. , 2002, Urology.

[93]  A. Sethi,et al.  Radiation exposure to the corporeal bodies during 3-dimensional conformal radiation therapy for prostate cancer. , 2002, The Journal of urology.

[94]  C. Catton,et al.  Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. , 2002, International journal of radiation oncology, biology, physics.

[95]  Michael W Kattan,et al.  Cancer control with radical prostatectomy alone in 1,000 consecutive patients. , 2002, The Journal of urology.

[96]  K. Wallner,et al.  Dosimetric and radiographic correlates to prostate brachytherapy‐related rectal complications , 2001, International journal of cancer.

[97]  Cedric Yu,et al.  Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer. , 2001, International journal of radiation oncology, biology, physics.

[98]  F. Vicini,et al.  Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy. , 2001, The Journal of urology.

[99]  J. Cherlow,et al.  High-dose-rate brachytherapy in the treatment of carcinoma of the prostate. , 2001, Cancer control : journal of the Moffitt Cancer Center.

[100]  C C Ling,et al.  High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. , 2001, The Journal of urology.

[101]  J. Blasko,et al.  Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. , 2001, Urology.

[102]  D. Grignon,et al.  Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. , 2001, International journal of radiation oncology, biology, physics.

[103]  C. Reddy,et al.  Radiation dose response in patients with favorable localized prostate cancer (Stage T1-T2, biopsy Gleason < or = 6, and pretreatment prostate-specific antigen < or = 10). , 2001, International journal of radiation oncology, biology, physics.

[104]  P. O'Brien,et al.  Radiation injury of the rectum. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[105]  A. Romagnoli,et al.  Roach's Mathematical Equations in Predicting Pathological Stage in Men with Clinically Localized Prostate Cancer , 2001, Tumori.

[106]  A. Renshaw,et al.  The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer. , 2001, International journal of radiation oncology, biology, physics.

[107]  N Lee,et al.  Factors predicting for postimplantation urinary retention after permanent prostate brachytherapy. , 2000, International journal of radiation oncology, biology, physics.

[108]  J. Manola,et al.  Identifying the predictors of acute urinary retention following magnetic-resonance-guided prostate brachytherapy. , 2000, International journal of radiation oncology, biology, physics.

[109]  P. Grimm,et al.  American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. , 1999, International journal of radiation oncology, biology, physics.

[110]  S. Turner,et al.  Sexual dysfunction after radical radiation therapy for prostate cancer: a prospective evaluation. , 1999, Urology.

[111]  A. Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[112]  J. Chin,et al.  CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group. , 1999, Urology.

[113]  R. Stock,et al.  Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. , 1998, The Journal of urology.

[114]  A. Renshaw,et al.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. , 1998, JAMA.

[115]  T E Schultheiss,et al.  Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. , 1998, International journal of radiation oncology, biology, physics.

[116]  M. Kattan,et al.  A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. , 1998, Journal of the National Cancer Institute.

[117]  R. Stock,et al.  A dose-response study for I-125 prostate implants. , 1998, International journal of radiation oncology, biology, physics.

[118]  A. Zietman,et al.  Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. , 1997, International journal of radiation oncology, biology, physics.

[119]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[120]  M. Zelefsky,et al.  Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. , 1997, Urology.

[121]  L. Verhey,et al.  Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. , 1995, International journal of radiation oncology, biology, physics.

[122]  C. Perez,et al.  Technical and tumor-related factors affecting outcome of definitive irradiation for localized carcinoma of the prostate. , 1993, International journal of radiation oncology, biology, physics.

[123]  T. Phan,et al.  High dose rate brachytherapy as a boost for the treatment of localized prostate cancer. , 2007, The Journal of urology.

[124]  Mark J Rivard,et al.  American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103. , 2007, Brachytherapy.

[125]  G. Gagnon,et al.  Combined external beam radiotherapy and Pd‐103 brachytherapy boost improves biochemical failure free survival in patients with clinically localized prostate cancer: Results of a matched pair analysis , 2005, The Prostate.

[126]  G. Gustafson,et al.  Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. , 2001, International journal of radiation oncology, biology, physics.

[127]  R. Stock,et al.  Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. , 2001, International journal of radiation oncology, biology, physics.

[128]  M. Zelefsky,et al.  Long-term urinary toxicity after 3-dimensional conformal radiotherapy for prostate cancer in patients with prior history of transurethral resection. , 2000, International journal of radiation oncology, biology, physics.

[129]  L. Potters,et al.  Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. , 1999, International journal of radiation oncology, biology, physics.

[130]  M. Zelefsky,et al.  Elucidating the etiology of erectile dysfunction after definitive therapy for prostatic cancer. , 1998, International journal of radiation oncology, biology, physics.

[131]  G E Hanks,et al.  Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[132]  P. Carroll,et al.  Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. , 1994, International journal of radiation oncology, biology, physics.

[133]  B Pickett,et al.  Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer. , 1994, International journal of radiation oncology, biology, physics.

[134]  J. Hopewell,et al.  Microvasculature and radiation damage. , 1993, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.